These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 33639911

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
    Kotwal A, Rouleau SG, Dasari S, Kottschade L, Ryder M, Kudva YC, Markovic S, Erickson D.
    J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
    [Abstract] [Full Text] [Related]

  • 24. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
    Manaka K, Sato J, Takeuchi M, Watanabe K, Kage H, Kawai T, Sato Y, Miyagawa T, Yamada D, Kume H, Sato S, Nagase T, Iiri T, Nangaku M, Makita N.
    Sci Rep; 2021 Jun 02; 11(1):11617. PubMed ID: 34078988
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
    Kurokawa R, Ota Y, Gonoi W, Hagiwara A, Kurokawa M, Mori H, Maeda E, Amemiya S, Usui Y, Sato N, Nakata Y, Moritani T, Abe O.
    AJNR Am J Neuroradiol; 2020 Sep 02; 41(9):1683-1689. PubMed ID: 32763900
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 02; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
    Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R.
    Endocr Relat Cancer; 2021 Jun 02; 28(7):419-431. PubMed ID: 33890870
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R.
    Thyroid; 2018 Oct 02; 28(10):1243-1251. PubMed ID: 30132401
    [Abstract] [Full Text] [Related]

  • 40. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N.
    Thyroid; 2017 Jul 02; 27(7):894-901. PubMed ID: 28537531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.